NZ717022A - Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators - Google Patents
Compositions comprising sphingosine 1 phosphate (s1p) receptor modulatorsInfo
- Publication number
- NZ717022A NZ717022A NZ717022A NZ71702208A NZ717022A NZ 717022 A NZ717022 A NZ 717022A NZ 717022 A NZ717022 A NZ 717022A NZ 71702208 A NZ71702208 A NZ 71702208A NZ 717022 A NZ717022 A NZ 717022A
- Authority
- NZ
- New Zealand
- Prior art keywords
- viral
- sphingosine
- phosphate
- compositions
- binary blend
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 1
- 206010047470 viral myocarditis Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229920000881 Modified starch Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Discloses herein is a stable binary blend of a pharmaceutical composition for oral administration, which comprises: (i) a compound selected from 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol (FTY720, fingolimod) in free form, a pharmaceutically acceptable salt thereof, and (ii) one excipient selected from the group consisting of:microcrystalline cellulose, sodium carboxymethyl starch, hydrogenated castor oil, povidone and pregelatinized starch. This binary blend is suitable for the treatment of organ or tissue transplant rejection, graft versus host disease, autoimmune diseases, inflammatory conditions, viral myocarditis, viral diseases caused by viral myocarditis or cancers.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97948207P | 2007-10-12 | 2007-10-12 | |
| NZ628686A NZ628686A (en) | 2007-10-12 | 2008-10-09 | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| NZ60646008 | 2008-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ717022A true NZ717022A (en) | 2017-09-29 |
Family
ID=55587918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ717022A NZ717022A (en) | 2007-10-12 | 2008-10-09 | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| NZ628686A NZ628686A (en) | 2007-10-12 | 2008-10-09 | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ628686A NZ628686A (en) | 2007-10-12 | 2008-10-09 | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
Country Status (1)
| Country | Link |
|---|---|
| NZ (2) | NZ717022A (en) |
-
2008
- 2008-10-09 NZ NZ717022A patent/NZ717022A/en unknown
- 2008-10-09 NZ NZ628686A patent/NZ628686A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ628686A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150838T1 (en) | Compositions comprising sphingosine i phosphate (sip) receptor modulators | |
| NZ542622A (en) | Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol | |
| CA2545503C (en) | Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases | |
| CY1121781T1 (en) | RASAGILLINE EXTENDED-RELEASE PHARMACEUTICAL FORM AND USES THEREOF | |
| EP2386299B1 (en) | 1-Amino-Alkylcyclohexane derivatives for use in the treatment of tinnitus associated with hearing loss | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| RU2012142811A (en) | PHARMACEUTICAL COMPOSITIONS AND ORAL ORAL DOSED FORMS OF LEVERODOPE'S MEDICINAL PRODUCTS AND METHODS OF APPLICATION | |
| NZ591999A (en) | Salts of fingolimod fty720 | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| EP3210633A3 (en) | Compositions and their uses directed to huntingtin | |
| JP2006522006A5 (en) | ||
| RU2011123371A (en) | CRYSTAL FORMS OF FINGOLIMODA HYDROCHLORIDE | |
| HK1142062A1 (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) | |
| MY148844A (en) | Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol | |
| PE20081106A1 (en) | CAPECITABIN PEDIATRIC TABLETS | |
| CL2013002810A1 (en) | Oral solid pharmaceutical composition comprising a) a 2-amino-2- [2- (4-octyl-phenyl) -ethyl] -propane-1,3-diol (fingolimod) compound in an amount of 0.5 mg or less , or a salt thereof, b) a filler and c) a stabilizer comprising a cyclodextrin; and its use to treat an autoimmune disease such as multiple sclerosis. | |
| US9145431B2 (en) | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof | |
| RU2008134143A (en) | PHARMACEUTICAL COMPOSITION OF CITYCOLINE, CHOLIN ALPHOSCERATE AND L-CARNITINE (OR ACETYL-L-CARNITINE) FOR THE TREATMENT AND PREVENTION OF DISEASES OF THE CENTRAL NERVOUS SYSTEM AND METHOD | |
| NZ717022A (en) | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators | |
| HRP20130225T1 (en) | Retardformulation comprising 3-(2-dimethylaminomethylcyclohexyl) phenol | |
| JP2018100280A (en) | Dosage regimen of diaryl sulfide derivatives | |
| PE20230105A1 (en) | DOSAGE FORM PROVIDING SUPPORTED RELEASE OF TAPENTADOL PHOSPHORIC ACID SALT | |
| RU2021123106A (en) | COMPOSITIONS CONTAINING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR MODULATORS | |
| NO332776B1 (en) | Nasal pharmaceutical composition of piribedil | |
| RU2012124232A (en) | PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMIELINIZATION DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 09 OCT 2018 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20180116 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2019 BY CPA GLOBAL Effective date: 20180920 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2020 BY CPA GLOBAL Effective date: 20190919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2021 BY CPA GLOBAL Effective date: 20200917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2022 BY CPA GLOBAL Effective date: 20210916 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2023 BY CPA GLOBAL Effective date: 20220923 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2024 BY CPA GLOBAL Effective date: 20230921 |